MXCT vs VRTX · rev $38.6M vs P/E 30, rev $12.00B
MaxCyte Inc (MXCT) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
MXCT currently screens at market cap $124.3M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the MXCT and VRTX stock pages for the full models.
Not investment advice.